1. Home
  2. DNUT vs DCTH Comparison

DNUT vs DCTH Comparison

Compare DNUT & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Krispy Kreme Inc.

DNUT

Krispy Kreme Inc.

HOLD

Current Price

$2.82

Market Cap

524.0M

ML Signal

HOLD

DCTH

Delcath Systems Inc.

HOLD

Current Price

$14.36

Market Cap

578.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DNUT
DCTH
Founded
1937
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Medical/Dental Instruments
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
524.0M
578.4M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
DNUT
DCTH
Price
$2.82
$14.36
Analyst Decision
Hold
Strong Buy
Analyst Count
7
5
Target Price
$4.08
★ $24.00
AVG Volume (30 Days)
★ 1.9M
251.9K
Earning Date
11-05-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 107.53
EPS
N/A
★ 0.04
Revenue
★ $1,522,616,000.00
N/A
Revenue This Year
N/A
$24.61
Revenue Next Year
$5.20
$24.27
P/E Ratio
★ N/A
$368.38
Revenue Growth
N/A
★ N/A
52 Week Low
$2.83
$8.12
52 Week High
$4.75
$17.42

Technical Indicators

Market Signals
Indicator
DNUT
DCTH
Relative Strength Index (RSI) 38.00 39.08
Support Level N/A $14.26
Resistance Level $3.72 $16.51
Average True Range (ATR) 0.12 0.51
MACD -0.00 -0.06
Stochastic Oscillator 2.70 17.28

Price Performance

Historical Comparison
DNUT
DCTH

About DNUT Krispy Kreme Inc.

Krispy Kreme Inc is a sweet-treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations world-wide. It derives maximum revenue from the U.S. segment.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: